Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending.
The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months.
In its update on trading for the year ending December 31st 201 Instem added that their clients' ability to contribute to current year results will only be known definitively at the year-end.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As a result, Instem now intends to announce its planned trading update in early January.
Shares of Instem fell 2.2% at 08:40 in London.
CJ
-
Giorgio Armani: the irreplaceable Il SignoreGiorgio Armani started his fashion business in 1975 and built it into the world’s largest private luxury brand. Where can it go without him?
-
A strange calm in creditCorporate bond markets remain remarkably relaxed, with yields that offer little compensation for risks
